|
Mar 12
|
iRobot, Target, Novo Nordisk vs. Roche: Market Minute
|
|
Mar 12
|
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
|
|
Mar 12
|
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
|
|
Mar 12
|
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
|
|
Mar 12
|
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
|
|
Mar 12
|
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
|
|
Mar 12
|
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
|
|
Mar 12
|
Roche broadens obesity drug plans with $1.65B Zealand deal
|
|
Mar 12
|
Zealand and Roche strike $5.3bn obesity treatment deal
|
|
Mar 3
|
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
|
|
Mar 2
|
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
|
|
Feb 28
|
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
|
|
Feb 28
|
Immune-Onc doses first subject in trial of IO-108 for HCC
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 12
|
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 12
|
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
|
|
Feb 10
|
Is Roche Holding AG (RHHBY) The Best Annual Dividend Stock To Buy Now?
|
|
Jan 30
|
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
|
|
Jan 30
|
FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay
|
|
Jan 30
|
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
|